Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 2

Status

Unknown 3

Sponsor Class

OTHER 134INDUSTRY 59NIH 6NETWORK 6OTHER_GOV 3UNKNOWN 2

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 2Tumor-Agnostic 1

Conditions

Breast Neoplasms 2Neoplasms 1

Interventions

Capecitabine 28apatinib 26Oxaliplatin 24Cisplatin 24tislelizumab 23Gemcitabine 23Irinotecan 19Paclitaxel 18Carboplatin 18Docetaxel 15Bevacizumab 15Fluorouracil 14Drug Therapy 13Cyclophosphamide 11pembrolizumab 10camrelizumab 10Vinorelbine 9Radiation 9S 1 (combination) 8Leucovorin 8Cetuximab 8toripalimab 7sintilimab 7Rituximab 7Erlotinib Hydrochloride 7pyrotinib 6Gefitinib 6Albumin-Bound Paclitaxel 6fludarabine 5anlotinib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × OTHER_GOV × Fulvestrant × Clear all
NCT05328440 2023-09-25

Treatment of Dalpiciclib Combined With Pyrotinib for Trastuzumab-sensitive HER2+ Advanced Breast Cancer(DAP-Her-02)

Henan Cancer Hospital

Phase 2 Unknown
120 enrolled
Breast

Breast Neoplasms

NCT03024580 2019-08-15

MEGA

Instituto Nacional de Cancer, Brazil

Phase 2 Unknown
20 enrolled
Breast

Breast Neoplasms

NCT02530411 2015-08-21

FURVA

Velindre NHS Trust

Phase 2 Unknown
160 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡